# A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

> **NCT06156527** · PHASE2 · RECRUITING · sponsor: **National Cancer Center, Korea** · enrollment: 120 (estimated)

## Conditions studied

- Lazertinib

## Interventions

- **DRUG:** Lazertinib
- **DRUG:** Bevacizumab Injectable Product

## Key facts

- **NCT ID:** NCT06156527
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-05
- **Primary completion:** 2026-09-05
- **Final completion:** 2026-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06156527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06156527, "A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06156527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*